تجاوز إلى المحتوى الرئيسي
عنوان الدراسة الجهاز رقم البروتوكول الراعي الحالة موقع الدراسة
"A multicenter, multinational, prospective, interventional,
single-arm, Phase IV study evaluating the clinical
efficacy and safety of 26 weeks of treatment with insulin glargine 300 U/mL (Gla-300) in patients with Type 2 diabetes mellitus uncontrolled
LPS15396
SANOFI
جاري Sultan bin Abdulaziz Humanitarian city (Riyadh)
An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, 105MS306
Biogen
جاري King Faisal Specialist Hospital and Research Center (Jeddah)
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical T S1007
King Faisal Specialist Hospital & Research Center
جاري King Faisal Specialist Hospital and Research Center (Riyadh)
"A Phase III Double-blind Randomised Study Assessing the Efficacy and
Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line
Treatment for Patients with Histologically Confirmed, Locally Advanced
(Inoperable) or Metastatic Tripl
D3614C00001
AstraZeneca
جاري King Fahad Specialist Hospital (Dammam)
A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Pre D8221C00001
Acerta Pharma BV جاري King Fahad Specialist Hospital (Dammam)
A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Endocrine Therapy Alone in Patients with High Risk Node Positive Early Stage Hormone Receptor Positive, Human Epidermal Receptor 2 Ne I3Y-MC-JPCF Eli Lilly جاري King Fahad Medical City (Riyadh)
"A PHASE III, MULTICENTER,
RANDOMISED, DOUBLEBLIND,
PLACEBOCONTROLLED
STUDY OF ATEZOLIZUMAB (ANTI−PDL1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED
MO39196 Roche




جاري International Medical Center (Jeddah)
Randomized, four-way, four-period, single oral dose, open-label, crossover, bioequivalence study to compare Tacrolimus Immediate-release capsules (5 mg tacrolimus) versus Prograf® Immediate-release capsules (5 mg tacrolimus), in 19-2017




MEDIS Laboratories




جاري Saudi Ajal
ATOS study_A 12–month prospective observational study assessing the real-world clinical effectiveness, safety and health-economic benefits of Toujeo® initiation after oral antidiabetic drug failure in insulin-naïve patients with type 2 diabetes melli OBS14708








SANOFI








جاري King Abdulaziz University Hospital (Jeddah)
Randomized, two-way, two-period, single injectable dose, open-label, crossover, bioequivalence study to compare Enoxa pre-filled syringes (80 mg enoxaparin sodium) versus Clexane® pre-filled syringes (80 mg enoxaparin sodium), in healthy 21-2017 v.02 MEDIS Laboratories جاري Saudi Ajal
عرض 21 - 30 من 118